{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:51:32Z","timestamp":1790949092080,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016041","name":"Queen Elizabeth Hospital Birmingham Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJUI Compass"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Stereotactic ablative radiotherapy (SABR) for primary renal cell carcinoma (RCC) is a promising non\u2010invasive ablative treatment option. A prospective interventional clinical trial published showed that treatment was feasible and well tolerated. We present the first single\u2010institution UK cohort of patients with primary RCC receiving protocol\u2010based SABR with prospective follow\u2010up. We also present a protocol that could be used to facilitate more widespread use of the treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Nineteen biopsy\u2010proven primary RCC patients were treated with either 42\u2009Gy in three fractions on alternate days or 26\u2009Gy in a single fraction based on predefined eligibility criteria using either Linear Accelerator or CyberKnife platform. Prospective toxicity data using CTCAE V4.0 and outcome data such as estimated glomerular filtration rate (eGFR) and tumour response using CT thorax, abdomen and pelvis (CT\u2010TAP) were collected at 6\u2009weeks, 3, 6, 12, 18 and 24\u2009months post treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 19 patients had a median age of 76\u2009years (interquartile range [IQR] 64\u201382\u2009years) and 47.4% were males, and they had a median tumour size of 4.5\u2009cm (IQR 3.8\u20135.2\u2009cm). Single and fractionated treatment was well tolerated and there were no significant acute side effects. The mean drop from baseline in eGFR at 6\u2009months was 5.4\u2009ml\/min and that at 12\u2009months was 8.7\u2009ml\/min. The overall local control rate at both 6 and 12\u2009months was 94.4%. Overall survival at 6 and 12\u2009months was 94.7% and 78.3%, respectively. After a median follow\u2010up of 17\u2009months, three patients experienced a Grade 3 toxicity, which was resolved with conservative management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>SABR for primary RCC is a safe and feasible treatment for medically unfit patients, which can be delivered in most UK cancer centres using standard Linear Accelerator as well as CyberKnife platforms.<\/jats:p><\/jats:sec>","DOI":"10.1002\/bco2.199","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T02:46:40Z","timestamp":1681440400000},"page":"464-472","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["First UK patient cohort treated with stereotactic ablative radiotherapy for primary kidney cancer"],"prefix":"10.1002","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3862-9299","authenticated-orcid":false,"given":"Anjali","family":"Zarkar","sequence":"first","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Henderson","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Carver","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Heyes","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Harrop","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Tutill","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kilkenny","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marshall","sequence":"additional","affiliation":[{"name":"Warwick Clinical Trials Unit  Warwick UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Elbeltagi","sequence":"additional","affiliation":[{"name":"Warwick Clinical Trials Unit  Warwick UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Howard","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"UK C.R.Kidney cancer treatment statistics.2022[cited 2022 January]. Available from:http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/kidney-cancer\/incidence"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.2007.113"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12349"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13811"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2017.09.007"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1118\/1.3438081"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4916-2"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12 <2519::AID-CNCR26>3.0.CO;2-E"},{"issue":"6","key":"e_1_2_9_10_1","first-page":"1100","article-title":"A generalized concept of equivalent uniform dose (EUD)","volume":"26","author":"Niemierko A","year":"1999","journal-title":"Med Phys"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.06.002"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.08.044"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.08.030"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.14.14099"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-019-0531-z"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2016.04.002"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-8-24"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10143-013-0504-8"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000435"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2014.10.003"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.11.047"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31156"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.02.089"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90171-Y"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.19.22213"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.06.218"}],"container-title":["BJUI Compass"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bco2.199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:33:12Z","timestamp":1759926792000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1002\/bco2.199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1002\/bco2.199"],"URL":"https:\/\/doi.org\/10.1002\/bco2.199","archive":["Portico"],"relation":{},"ISSN":["2688-4526","2688-4526"],"issn-type":[{"value":"2688-4526","type":"print"},{"value":"2688-4526","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"assertion":[{"value":"2022-07-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}